Gʀᴇɢᴏʀʏ Rɪᴇʟʏ
@RielyMD
Followers
4K
Following
12K
Media
647
Statuses
7K
Medical Oncologist in NYC. Ning Zhao and Ge Li Endowed Chair. Lung and thymic cancer. COI: https://t.co/2CQnmp2MMz
New York, NY
Joined May 2011
This is an important paper for thinking about MTAP in NSCLC. Several new synthetic lethal approaches to these cancers are in the clinic. Uniquely for NSCLC, seems to co-occur frequently with many classical driver alterations, but not with KRAS.
Nice to see this online from @KCArbourMD @JessieStuart316 and colleagues. Shows overlap of MTAP deletions and EGFR mutations. Both at baseline and resistance. Example of potential approach to treatment. @IASLC @JTOonline @MSKCancerCenter
https://t.co/hSLn9dKgaq
0
1
9
Nice to see this online from @KCArbourMD @JessieStuart316 and colleagues. Shows overlap of MTAP deletions and EGFR mutations. Both at baseline and resistance. Example of potential approach to treatment. @IASLC @JTOonline @MSKCancerCenter
https://t.co/hSLn9dKgaq
2
7
21
Bad cancers but a great conference, thanks @BalazsHalmosMD @ChaftJamie
Great presentation from @bherzbergmd on tough targets in thoracic cancers (SMARCA4, NUT, STK11/KEAP1, etc). @gotoPER New York Lung
0
1
5
Incredible discussions at the 20th anniversary of #NYL conference with challenging cases and fantastic panel! Congrats @BalazsHalmosMD and @ChaftJamie 👏🏽👏🏽👏🏽
1
3
28
At @gotoPER New York Lung, @charlesrudin showing trials and investigators representing future approaches in small cell lung cancer
1
2
4
Great presentation from @bherzbergmd on tough targets in thoracic cancers (SMARCA4, NUT, STK11/KEAP1, etc). @gotoPER New York Lung
0
1
4
Want to better understand the implications of the lung data presented at #WCLC25 & #ESMO25 ? Do register for this event to hear from @MarianaBrandao0 @RielyMD and I placing it all in context
Interested in hearing more about recent progress with #checkpointinhibitors in #LungCancer? 🤔 Join us for our Advances in #LungCancer Webinar! 🫁 💻 Featuring presentations & expert discussions on the latest breakthroughs and #clinical developments in #lungcancer, with a focus
0
5
14
Be there! Do register, there’s a lot of outputs from #ESMO25 to drill into @MarianaBrandao0 @RielyMD
Join the Advances in Lung Cancer 2025 Highlights webinar on Dec 1, 2025, at 7:30 PM (CET) for an expert-led virtual session hosted by @VJOncology , featuring the latest clinical breakthroughs, trial updates, and insights from major 2025 lung cancer meetings including ELCC, ASCO,
0
8
16
The FRONT-BRAF study, investigating the optimal 1st-line treatment for patients w/ stage IV BRAF V600E-mut NSCLC, has just been published in @TheLancetOncol
https://t.co/ijbh8g3iwk This is a global effort involving 17 major cancer centres across Italy, USA, France, & Brazil. 1/9
1
19
54
Nearly 1 in 3 neurologists in the US trained abroad. Immigrant neurologists fill critical gaps in underserved communities but face visa barriers & uncertainty. Supporting them is essential for equitable neurologic care. My latest in @GreenJournal
https://t.co/XEqOK0VeI6
neurology.org
1
5
34
Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work led to this moment, made possible by an amazing team! 🧵 🪡
cell.com
Osorio et al. report a first-in-human study of intratumoral 2141-V11, an Fc-engineered CD40 agonistic antibody, showing it is safe and induces systemic and durable antitumor immunity in patients with...
9
23
99
I agree, Breakthrough is a great read for anyone who wishes to understand how new & transformative therapeutics are created and developed
New book out, by William Pao. Great stories about developing drugs. Definitely covers EGFR, but other important medicines as well. It is a great read.
2
5
31
Thanks to better treatments, people are living longer after a #lungcancer diagnosis, with many being cured. And close management of those who have had successful treatment is more important than ever. MSK’s Lung Cancer Survivorship Program provides regular screening for
1
3
14
New book out, by William Pao. Great stories about developing drugs. Definitely covers EGFR, but other important medicines as well. It is a great read.
5
8
75
Predatory Journals — What Can We Do to Protect Their Prey? | New England Journal of Medicine: The number of predatory journals is difficult to accurately determine but was estimated at more than 15,000 in 2021
nejm.org
An editorial from the International Committee of Medical Journal Editors recommends actions that authors, institutions, funders, journal editors, and publishers can take to protect against predator...
0
4
10
Attempts to enter the Congestion Relief zone with alter/covered fraudulent plates could subject you to arrest and/or fines. These attempts occurred at 2nd Ave & 60th St and 57th St between 9th & 10th Ave.
351
89
2K
The only way you'd spend $27 is by taking a NJ tunnel without EZ Pass. FDNY Firefighters aren't even allowed to live in NJ!
Map shows Congestion Pricing will cost up to $27 to drive into Manhattan: Firefighters, teachers and businesses can’t afford it https://t.co/q5sBwQFV6f
31
87
2K
Today, Christmas Eve, received a 2,070 page document of SUSARs, as part of role as CI for a trial 😡 Is there anything more pointless? Guaranteed to ensure content, and potentially important information, goes unread How we approach safety data needs a complete reset
2
3
14
A record 77 new ADCs entered clinical development in 2024 (including those accepted but not yet started). Payload class was clearly dominated by topo1i with 55 ADCs. Greater diversity was observed in antibody targets, featuring novel TAAs and several bispecific ADCs.
5
56
206
Can't even die in peace
Hospices owned by private equity firms or publicly traded companies had significantly lower caregiver-reported quality scores compared to both non-profit and other for-profit hospices. https://t.co/J6JiVy8QrY
1
1
20